Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Jounce, Concentra Pounces On Atea

COVID-19 Antiviral Firm Could Be Snapped Up

Executive Summary

Concentra's unsolicited bid for Atea is the latest proof that promising but financially strapped biotechs that are trading below cash are prime M&A targets.

You may also be interested in...



Egetis Ends Takeover Talks To Focus On Emcitate

The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.

BenevolentAI Slashes Jobs And Drug Programs

The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.

BMS Trumpets Breakthrough For Phase III-Bound IPF Drug

Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel